Sangamo Therapeutics, Inc. (SGMO)
NASDAQ: SGMO · Real-Time Price · USD
1.880
-0.080 (-4.08%)
Nov 22, 2024, 4:00 PM EST - Market closed
Sangamo Therapeutics Employees
Sangamo Therapeutics had 405 employees as of December 31, 2023. The number of employees decreased by 73 or -15.27% compared to the previous year.
Employees
405
Change (1Y)
-73
Growth (1Y)
-15.27%
Revenue / Employee
$129,114
Profits / Employee
-$332,938
Market Cap
392.26M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
DocGo | 4,164 |
Canopy Growth | 1,029 |
Revance Therapeutics | 597 |
AirSculpt Technologies | 381 |
Akebia Therapeutics | 167 |
KalVista Pharmaceuticals | 150 |
Acelyrin | 135 |
Foghorn Therapeutics | 116 |
SGMO News
- 4 days ago - Sangamo Therapeutics Announces U.S. FDA Clearance of IND Application for ST-503 for the Treatment of Idiopathic Small Fiber Neuropathy, a Type of Chronic Neuropathic Pain - Business Wire
- 11 days ago - Sangamo Therapeutics, Inc. (SGMO) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 11 days ago - Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results - Business Wire
- 19 days ago - Sangamo Therapeutics Announces Third Quarter 2024 Conference Call and Webcast - Business Wire
- 4 weeks ago - Sangamo: Fabry Disease Gene Therapy Moves Forward With Positive FDA Regulatory Development - Seeking Alpha
- 4 weeks ago - Sangamo Therapeutics Announces Alignment With FDA on Accelerated Approval Pathway for ST-920 in Fabry Disease With BLA Submission Expected in 2025 - Business Wire
- 4 weeks ago - Sangamo Follow-Up: Giro-Vec And STAC-BBB? Check. - Seeking Alpha
- 3 months ago - Sangamo Therapeutics, Inc. (SGMO) Q2 2024 Earnings Call Transcript - Seeking Alpha